FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954693732> ?p ?o ?g. }

• W2954693732 endingPage "CT006" @default.
• W2954693732 startingPage "CT006" @default.
• W2954693732 abstract "Abstract Despite recent advances in cancer treatment by immune checkpoint blockade therapies, the overall response rate is still low in patients with advanced malignancies. Therapeutic cancer vaccines designed to reactivate T cells against tumor cells has achieved great progress. Neoantigens arisen from tumor somatic mutations provide tumor specific targets for developing personalized cancer vaccines, which are able to elicit strong T cell mediated immune responses due to the immunogenicity and the overcoming immune tolerance. Therefore, we developed a peptide-based personalized cancer vaccines (iNeo-Vac-P01) to mobilize immunity against a spectrum of tumor neoantigens, and initiated a clinical trial (NCT03662815). This study was a single-arm, open-label, Phase I trial, carried out in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine in China with approval by the institutional review board and independent ethics committee. The main objectives were to assess safety, progression-free survival (PFS) and overall survival (OS). Patients with advanced malignancies were enrolled. For each patient, Exome-seq and RNA-seq was conducted. The analyses of somatic mutations, tumor neoantigens, as well as neoantigen prioritization and long peptide design, were performed by in-house pipeline (iNeo). The clinical-grade long peptides incorporating multiple neo-epitopes of both HLA class I and II were synthesized. The iNeo-Vac-P01 consisting of 10~20 long peptides per patient (grouped into 3~4 pools with 0.1mg of each peptide) was administered subcutaneously on day 1, 4, 8, 15, and 22 (priming phase) and day 78 and 162 (booster phase) with GM-CSF as adjuvant. The Cox regression model was used to assess the risk factors for OS and PFS. Total 30 patients were enrolled with different cancer types, including non-small cell lung cancer, pancreatic cancer, colorectal cancer, melanoma, ovarian cancer and others. The iNeo-Vac-P01 vaccines were successfully manufactured and administered for all patients. None of them had a grade 3 or 4 adverse event. 18 of them completed priming phase were included in the efficacy evaluation. The disease control rate (percentage of patients whose best response was not PD) was 75%. The median PFS was 5.37 months, and the median OS was not available yet. Overall, T cell responses were detected against 80% of peptide pools by ELISpot assays using post-vaccination blood samples. No response was detected in pre-vaccination blood samples, except for 2 patients who underwent pretreatment of radiofrequency ablation (RFA), which might cause tumor antigens release to trigger immune response. The preliminary results of this study demonstrated that iNeo-Vac-P01 was feasible, safe, able to elicit T cell mediated immune response specifically targeting tumor cells, and beneficial to patients with advanced diseases. The pre-existing responses against vaccine peptides in two patients with RFA pretreatment suggested that neoantigens incorporated in iNeo-Vac-P01 were accurately predicted. Citation Format: Yong Fang, Jiawei Shou, Fan Mo, Huimin Wang, Shanshan Zhang, Hongsen Li, Xiaoyun Zhou, Hongming Pan, Shuqing Chen. Clinical study of a personalized neoantigen cancer vaccine in treating patients with advanced malignant tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT006." @default.
• W2954693732 created "2019-07-12" @default.
• W2954693732 creator A5020089499 @default.
• W2954693732 creator A5026665354 @default.
• W2954693732 creator A5032522966 @default.
• W2954693732 creator A5045030972 @default.
• W2954693732 creator A5045553246 @default.
• W2954693732 creator A5057723713 @default.
• W2954693732 creator A5058481549 @default.
• W2954693732 creator A5059519440 @default.
• W2954693732 creator A5078888279 @default.
• W2954693732 date "2019-07-01" @default.
• W2954693732 modified "2023-10-12" @default.
• W2954693732 title "Abstract CT006: Clinical study of a personalized neoantigen cancer vaccine in treating patients with advanced malignant tumor" @default.
• W2954693732 doi "https://doi.org/10.1158/1538-7445.am2019-ct006" @default.
• W2954693732 hasPublicationYear "2019" @default.
• W2954693732 type Work @default.
• W2954693732 sameAs 2954693732 @default.
• W2954693732 citedByCount "2" @default.
• W2954693732 countsByYear W29546937322020 @default.
• W2954693732 countsByYear W29546937322021 @default.
• W2954693732 crossrefType "journal-article" @default.
• W2954693732 hasAuthorship W2954693732A5020089499 @default.
• W2954693732 hasAuthorship W2954693732A5026665354 @default.
• W2954693732 hasAuthorship W2954693732A5032522966 @default.
• W2954693732 hasAuthorship W2954693732A5045030972 @default.
• W2954693732 hasAuthorship W2954693732A5045553246 @default.
• W2954693732 hasAuthorship W2954693732A5057723713 @default.
• W2954693732 hasAuthorship W2954693732A5058481549 @default.
• W2954693732 hasAuthorship W2954693732A5059519440 @default.
• W2954693732 hasAuthorship W2954693732A5078888279 @default.
• W2954693732 hasConcept C121608353 @default.
• W2954693732 hasConcept C126322002 @default.
• W2954693732 hasConcept C143998085 @default.
• W2954693732 hasConcept C147483822 @default.
• W2954693732 hasConcept C195616568 @default.
• W2954693732 hasConcept C203014093 @default.
• W2954693732 hasConcept C2776789287 @default.
• W2954693732 hasConcept C2777701055 @default.
• W2954693732 hasConcept C2778378633 @default.
• W2954693732 hasConcept C2780674031 @default.
• W2954693732 hasConcept C2780868878 @default.
• W2954693732 hasConcept C535046627 @default.
• W2954693732 hasConcept C71924100 @default.
• W2954693732 hasConcept C8891405 @default.
• W2954693732 hasConceptScore W2954693732C121608353 @default.
• W2954693732 hasConceptScore W2954693732C126322002 @default.
• W2954693732 hasConceptScore W2954693732C143998085 @default.
• W2954693732 hasConceptScore W2954693732C147483822 @default.
• W2954693732 hasConceptScore W2954693732C195616568 @default.
• W2954693732 hasConceptScore W2954693732C203014093 @default.
• W2954693732 hasConceptScore W2954693732C2776789287 @default.
• W2954693732 hasConceptScore W2954693732C2777701055 @default.
• W2954693732 hasConceptScore W2954693732C2778378633 @default.
• W2954693732 hasConceptScore W2954693732C2780674031 @default.
• W2954693732 hasConceptScore W2954693732C2780868878 @default.
• W2954693732 hasConceptScore W2954693732C535046627 @default.
• W2954693732 hasConceptScore W2954693732C71924100 @default.
• W2954693732 hasConceptScore W2954693732C8891405 @default.
• W2954693732 hasIssue "13_Supplement" @default.
• W2954693732 hasLocation W29546937321 @default.
• W2954693732 hasOpenAccess W2954693732 @default.
• W2954693732 hasPrimaryLocation W29546937321 @default.
• W2954693732 hasRelatedWork W2006650555 @default.
• W2954693732 hasRelatedWork W2020306777 @default.
• W2954693732 hasRelatedWork W2111140175 @default.
• W2954693732 hasRelatedWork W2141342965 @default.
• W2954693732 hasRelatedWork W2327043232 @default.
• W2954693732 hasRelatedWork W2763883091 @default.
• W2954693732 hasRelatedWork W3094151083 @default.
• W2954693732 hasRelatedWork W3192209904 @default.
• W2954693732 hasRelatedWork W4291367166 @default.
• W2954693732 hasRelatedWork W4360983034 @default.
• W2954693732 hasVolume "79" @default.
• W2954693732 isParatext "false" @default.
• W2954693732 isRetracted "false" @default.
• W2954693732 magId "2954693732" @default.
• W2954693732 workType "article" @default.